Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial

Figure 1 Patient flowchart. COVID-19: Coronavirus disease 2019.

Figure 2 Waterfall plot of the best response of the patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, as per response evaluation criteria in solid tumors (RECIST 1. 1).

Figure 3 Kaplan-Meier curves for patients receiving nab-paclitaxel plus capecitabine. A: Progression-free survival; B: Overall survival. PFS: Progression-free survival; OS: Overall survival.

Figure 4 Kaplan-Meier curves for patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. A: Progression-free survival; B: Overall survival. PFS: Progression-free survival; OS: Overall survival; GBC: Gallbladder cancer; ICC: Intrahepatic cholangiocarcinoma; ECC: Extrahepatic cholangiocarcinoma.